Targeted Therapy Shrinks Advanced Gastrointestinal Tumours for 65% of Patients in an Early Study
June 02, 2026
June 02, 2026
LONDON, England, June 2 (TNSxrep) -- The Royal Marsden National Health Service Foundation Trust issued the following news:
* * *
New targeted therapy shrinks advanced gastrointestinal tumours for 65% of patients in an early study
65% of patients who received velzatinib as first-line therapy experienced tumour shrinkage of 30 per cent or over, with all patients showing some reduction in tumour size.
*
A new, targeted cancer therapy . . .
* * *
New targeted therapy shrinks advanced gastrointestinal tumours for 65% of patients in an early study
65% of patients who received velzatinib as first-line therapy experienced tumour shrinkage of 30 per cent or over, with all patients showing some reduction in tumour size.
*
A new, targeted cancer therapy . . .